Advicenne Stock

ALDVI

FR0013296746

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 11:55:00 2026-08-11 EDT			5-day change	1st Jan Change
1.602 ^EUR	-0.87%		-2.32%	-7.40%

07-21	Advicenne's Distal Renal Tubular Acidosis Medicine Secures Reimbursement in Spain	MT
07-16	Advicenne S.A. Reports Sales Results for the First Half of 2026	CI

Analysts' recommendations: Advicenne

24-09-19

Advicenne: TP ICAP Midcap lowers its target

More recommendations

News in other languages: Advicenne

07-20	Le produit phare d'Advicenne remboursé en Espagne
07-20	Advicenne annonce le remboursement de Sibnayal® dans le traitement de l’ATRd en Espagne
07-16	Advicenne : Le chiffre d’affaires net du premier semestre 2026 porté par le remboursement de Sibnayal® et Likozam® en France
07-01	Advicenne annonce le renouvellement illimité de l’Autorisation de Mise sur le Marché de Sibnayal® au Royaume-Uni
06-23	Bourse : Sanofi enchaîne les AMM, Prysmian enchaîne les contrats, l'IA enchaîne les dépenses

More news

Managers and Directors: Advicenne

Manager	Title	Age	Since
Didier Laurens CEO	Chief Executive Officer	59	2021-05-02
Delphine Dumas CTO	Chief Tech/Sci/R&D Officer	-	2025-08-31
Véronique Leblanc CTO	Chief Tech/Sci/R&D Officer	-	2023-03-31

Director	Title	Age	Since
André Ulmann BRD	Director/Board Member	-	2017-06-22
Catherine Dunand BRD	Director/Board Member	64	2017-03-08
Charlotte Sibley BRD	Director/Board Member	78	2018-09-19

More insiders

Advicenne specializes in the research and development of drugs for the treatment of neglected neurological and nephrological diseases, mostly among children. At the end of 2025, the group had one product in clinical development phase: ADV7103 for the treatment of distal renal tubular acidosis and for the treatment of cystinuria.

Employees

Sector

Pharmaceuticals

Calendar

09-16 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
26-08-11	€1.602	-0.87%	42,844
26-08-10	€1.616	-2.65%	65,029
26-08-07	€1.660	-1.19%	58,441
26-08-06	€1.680	+1.94%	57,574
26-08-05	€1.648	+0.49%	62,799

Real-time Euronext Paris

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.602EUR

Average target price

4.000EUR

Spread / Average Target

+149.69%

Consensus

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Stock Market
Stocks
ALDVI Stock

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

Market Cap	23.31M 26.89M 21.82M 19.91M 37.46M 2.57B 38.09M 256M 100M 1.28B 101M 98.78M 4.28B	P/E 2026 *	-3.41x	P/E 2027 *	-3.64x
Enterprise Value	46.41M 53.55M 43.44M 39.64M 74.59M 5.11B 75.85M 509M 200M 2.56B 201M 197M 8.53B	EV / Sales 2026 *	7.03x	EV / Sales 2027 *	6.56x
Free-Float	95.15%	Yield 2026 *	-	Yield 2027 *	-

1 day	-0.87%
1 week	-2.32%
Current month	-2.32%
1 month	-9.49%
3 months	+70.43%
6 months	-23.17%
Current year	-7.40%

1 week	1.58	1.75
1 month	1.43	1.94
Current year	0.8	2.35
1 year	0.8	2.35
3 years	0.8	3.5
5 years	0.8	10.5
10 years	0.8	16.25

Date	Insider	Type	Main position	Quantity	% Market Cap.
12/30/20	Nathalie Lemarié	Sell	General Counsel	998	0.0123%
12/29/20	Nathalie Lemarié	Sell	General Counsel	1,000	0.0124%
12/25/20	Nathalie Lemarié	Sell	General Counsel	1,000	0.0124%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ADVICENNE	-0.87%	-2.32%	+36.46%	-52.67%	26.89M
REGENERON PHARMACEUTICALS, INC.	-1.37%	+4.78%	+45.99%	-1.23%	79.58B
SAMSUNG BIOLOGICS CO.,LTD.	+2.55%	+9.01%	+1.40%	+30.65%	52.73B
UCB	+0.49%	+1.30%	+21.22%	+175.79%	49.77B
CSL LIMITED	-0.30%	+5.59%	-47.80%	-47.54%	46.77B
BIOGEN INC.	-1.56%	-2.19%	+59.29%	-25.50%	30.13B
INCYTE CORPORATION	-0.39%	+0.39%	+52.89%	+83.63%	24.54B
MODERNA, INC.	+1.27%	+6.28%	+137.81%	-40.32%	24.18B
INNOVENT BIOLOGICS, INC.	-0.21%	+5.59%	+9.22%	+194.29%	21.2B
ALTEOGEN INC.	-5.89%	+22.69%	-0.99%	+796.32%	16.14B
Average	-0.62%	+164.78%	+31.55%	+111.34%	34.51B
Weighted average by Cap.	-0.26%	+270.03%	+26.52%	+73.39%

Advicenne Stock

Stocks

ALDVI

FR0013296746

Pharmaceuticals

Valuation: Advicenne

Chart: Advicenne

Latest news : Advicenne

Analysts' recommendations: Advicenne

Press Releases: Advicenne

News in other languages: Advicenne

Quotes and Performance

Course Extremes

Managers and Directors: Advicenne

Latest insider transactions

Biopharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Annual profits - Rate of surprise

07-20	Advicenne Announces the Reimbursement of Sibnayal® for the Treatment of dRTA in Spain	BU
07-16	Advicenne: Net Revenue for the First Half of 2026 Driven by Reimbursement of Sibnayal® and Likozam® in France	BU
07-01	Advicenne Announces the Unlimited Renewal of the Marketing Authorization for Sibnayal® in the United Kingdom	BU
06-23	Advicenne secures its cash runway to Q2 2027 through a bond financing of a nominal amount of up to EUR3.8 million	AQ
06-22	Advicenne Secures Its Cash Runway to Q2 2027 through a Bond Financing of a Nominal Amount of up to €3.8 Million	BU

	2026 *	2027 *
Net sales	6.6M 7.62M 6.18M 5.64M 10.61M 726M 10.79M 72.45M 28.39M 364M 28.6M 27.97M 1.21B	8M 9.23M 7.49M 6.83M 12.86M 880M 13.08M 87.82M 34.41M 441M 34.66M 33.91M 1.47B
Net income	-6.7M -7.73M -6.27M -5.72M -10.77M -737M -10.95M -73.55M -28.82M -369M -29.03M -28.4M -1.23B	-6.2M -7.15M -5.8M -5.3M -9.97M -682M -10.13M -68.06M -26.67M -342M -26.86M -26.28M -1.14B
Net Debt	23.1M 26.66M 21.63M 19.73M 37.13M 2.54B 37.76M 254M 99.35M 1.27B 100M 97.9M 4.25B	29.2M 33.69M 27.34M 24.94M 46.94M 3.21B 47.73M 321M 126M 1.61B 127M 124M 5.37B